Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience

被引:104
作者
Crooke, Stanley T. [1 ]
Baker, Brenda F. [1 ]
Xia, Shuting [1 ]
Yu, Rosie Z. [1 ]
Viney, Nicholas J. [1 ]
Wang, Yanfeng [1 ]
Tsimikas, Sotirios [1 ]
Geary, Richard S. [1 ]
机构
[1] Ionis Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92011 USA
关键词
antisense; oligonucleotide; assessment; clinical trials; triantennary N-acetylgalactosamine; TARGETING HUMAN LIPOPROTEIN; MESSENGER-RNA; SHAM CONTROL; PHARMACOKINETICS; DELIVERY; PHARMACOLOGY; DISPOSITION; INHIBITION; NUSINERSEN; POTENCY;
D O I
10.1089/nat.2018.0753
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Advances in medicinal chemistry have produced new chemical classes of antisense oligonucleotides (ASOs) with enhanced therapeutic properties. Conjugation of the triantennary N-acetylgalactosamine (GalNAc(3)) moiety to the extensively characterized phosphorothioate (PS)-modified 2 '-O-methoxyethyl (2 ' MOE) ASO exemplifies such an advance. This structure-activity optimized moiety effects receptor-mediated uptake of the ASO prodrug through the asialoglycoprotein receptor 1 to support selective targeting of RNAs expressed by hepatocytes. In this study we report the integrated assessment of data available from randomized placebo-controlled dose-ranging studies of this chemical class of ASOs administered systemically to healthy human volunteers. First, we compare the pharmacokinetic and pharmacodynamic profiles of a subset of the GalNAc(3)-conjugated PS-modified 2 ' MOE ASOs to the parent PS-modified 2 ' MOE ASOs for which plasma analytes are available. We then evaluate the safety profile of the full set of GalNAc(3)-conjugated PS-modified 2 ' MOE ASO conjugates by the incidence of signals in standardized laboratory tests and by the mean laboratory test results as a function of dose level over time. With hepatocyte targeted delivery, the ED50 for the GalNAc(3)-conjugated PS-modified 2 ' MOE ASO subset ranges from 4 to 10 mg/week, up to 30-fold more potent than the parent PS-modified 2 ' MOE ASO. No GalNAc(3)-conjugated PS-modified 2 ' MOE ASO class effects were identified from the assessment of the integrated laboratory test data across all doses tested with either single or multidose regimens. The increase in potency supports an increase in the safety margin for this new chemical class of ASOs now under broad investigation in the clinic. Although the total exposure is limited in the initial phase 1 trials, ongoing and future investigations in patient populations will support evaluation of the effects of long-term exposure.
引用
收藏
页码:16 / 32
页数:17
相关论文
共 50 条
[1]
Ammala C, 2017, DIABETES, V66, pA568
[2]
[Anonymous], 2017, J CLIN LIPIDOL
[3]
Bennett C. F., 2008, ANTISENSE DRUG TECHN, P273
[4]
Pharmacology of Antisense Drugs [J].
Bennett, C. Frank ;
Baker, Brenda F. ;
Nguyen Pham ;
Swayze, Eric ;
Geary, Richard S. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 57, 2017, 57 :81-105
[5]
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis [J].
Benson, M. D. ;
Waddington-Cruz, M. ;
Berk, J. L. ;
Polydefkis, M. ;
Dyck, P. J. ;
Wang, A. K. ;
Plante-Bordeneuve, V. ;
Barroso, F. A. ;
Merlini, G. ;
Obici, L. ;
Scheinberg, M. ;
Brannagan, T. H., III ;
Litchy, W. J. ;
Whelan, C. ;
Drachman, B. M. ;
Adams, D. ;
Heitner, S. B. ;
Conceicao, I. ;
Schmidt, H. H. ;
Vita, G. ;
Campistol, J. M. ;
Gamez, J. ;
Gorevic, P. D. ;
Gane, E. ;
Shah, A. M. ;
Solomon, S. D. ;
Monia, B. P. ;
Hughes, S. G. ;
Kwoh, T. J. ;
McEvoy, B. W. ;
Jung, S. W. ;
Baker, B. F. ;
Ackermann, E. J. ;
Gertz, M. A. ;
Coelho, T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :22-31
[6]
Crooke S.T., 2008, ANTISENSE DRUG TECHN, P3
[7]
The Effects of 2-O-Methoxyethyl Oligonucleotides on Renal Function in Humans [J].
Crooke, Stanley T. ;
Baker, Brenda F. ;
Pham, Nguyen C. ;
Hughes, Steven G. ;
Kwoh, T. Jesse ;
Cai, Danlin ;
Tsimikas, Sotirios ;
Geary, Richard S. ;
Bhanot, Sanjay .
NUCLEIC ACID THERAPEUTICS, 2018, 28 (01) :10-22
[8]
RNA-Targeted Therapeutics [J].
Crooke, Stanley T. ;
Witztum, Joseph L. ;
Bennett, C. Frank ;
Baker, Brenda F. .
CELL METABOLISM, 2018, 27 (04) :714-739
[9]
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials [J].
Crooke, Stanley T. ;
Baker, Brenda F. ;
Witztum, Joseph L. ;
Kwoh, Jesse ;
Pham, Nguyen C. ;
Salgado, Nelson ;
McEvoy, Bradley W. ;
Cheng, Wei ;
Hughes, Steven G. ;
Bhanot, Sanjay ;
Geary, Richard S. .
NUCLEIC ACID THERAPEUTICS, 2017, 27 (03) :121-129
[10]
Cellular uptake and trafficking of antisense oligonucleotides [J].
Crooke, Stanley T. ;
Wang, Shiyu ;
Vickers, Timothy A. ;
Shen, Wen ;
Liang, Xue-hai .
NATURE BIOTECHNOLOGY, 2017, 35 (03) :230-237